Innocutis Introduces Dexter the Dystrophic Nail to Educate the Public on Nail Dystrophy

CHARLESTON, S.C., April 16, 2014 — Innocutis, a specialty pharmaceutical company in Dermatologic and Podiatric specialties, is pleased to announce that Nuvail [poly-ureaurethane, 16%] is currently the #1 Prescribed Brand for Nail Dystrophy in both dermatology and podiatry. Nail Dystrophy affects a vast portion of the U.S. population and the medical community has had limited […]

Innocutis Holdings LLC Licenses “Sitavig” from BioAlliance Pharma

CHARLESTON, S.C., March 19, 2014 /PRNewswire/ – Innocutis Holdings LLC, an innovative pharmaceutical company dedicated to marketing best-in-class branded prescription products in skin-related therapies, is pleased to announce the licensing of Sitavig® (ACYCLOVIR) 50mg Buccal Tablets, from BioAlliance Pharma for the North American markets.  Sitavig represents a breakthrough in the herpes treatment category, which is comprised […]

Nuvail featured in O The Oprah Magazine

As Featured in O THE OPRAH MAGAZINE – March 2013 – Ask Val page 92 Q: My nails crack and split in winter. Are there any treatments that really work? A: Funny you should ask. Well, actually, not funny. I have the same problem and I’ve never found myself laughing about it. Since dryness is […]

Innocutis announces the FDA approval of Nuvail™ (poly-ureaurethane, 16%) nail solution

Charleston, SC August 2012 Innocutis is pleased to announce the FDA approval of Nuvail™ (poly-ureaurethane, 16%) nail solution, a novel prescription product to help manage fragile, damaged or brittle nails with cracking or splitting, a condition medically referred to as “nail dystrophy”. Among the most common forms of nail dystrophy is Brittle Nail Syndrome (BNS), […]

Innocutis announces three new prescribing options of Bionect®

Charleston, SC August 2012 Innocutis is pleased to announce the introduction of three new prescribing options of Bionect® (hyaluronic acid sodium salt 0.2%): an aqueous base 20ml spray, and aqueous base 100g cream and gel formulations. Available by prescription only, Bionect is formulated using a patented low molecular weight hyaluronic acid (LMWHA) and is indicated […]

DARA BioSciences Obtains U.S. Rights to Co-Promote Bionect®

DARA BioSciences Obtains U.S. Rights to Co-Promote Bionect(R), an FDA Approved Topical Hyaluronic Acid, Exclusively in the Radiation and Oncology Markets Bionect(R) Strengthens DARA’s Growing Portfolio of In-Licensed Oncology and Oncology Supportive Care Products RALEIGH, N.C., March 26, 2012 (GLOBE NEWSWIRE) — DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive agreement […]

Charleston-based Innocutis gets $6.5M investment

Brendan Kearney, Post & Courier Charleston-based dermatology drug and device firm Innocutis Holdings LLC announced Monday that it has received a $6.5 million investment from a Florida venture capital fund. Innocutis, which specializes in late-stage marketing, received the cash infusion from Ballast Point Ventures almost five months ago, around the same time the company changed […]

Innocutis Medical Signs Exclusive Marketing Agreement for INSORB Absorbable Skin Stapler

CHARLESTON, S.C.–(BUSINESS WIRE)–Innocutis Medical, a dermatology company focused on novel surgical devices and specialty pharmaceuticals, is pleased to announce an exclusive marketing agreement with Incisive Surgical, Inc. (Plymouth MN) for the sales and marketing rights within the dermatology market for the patented INSORB® Absorbable Skin Stapler, a revolutionary new modality for skin closure. The INSORB […]